# Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

> **NCT00458107** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 64 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SCA-136

## Key facts

- **NCT ID:** NCT00458107
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458107, "Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00458107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*